This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.81% per year. These returns cover a period from January 1, 1988 through September 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Shire Gets Positive CHMP Opinion for Hemophilia A Drug
by Zacks Equity Research
Shire's (SHPG) hemophilia A drug, Adynovi, gets positive opinion by the Committee for Medicinal Products for Human Use of the European Medicines Agency.
Alnylam RNAi Drug Gets Accelerated Assessment Grant From EMA
by Zacks Equity Research
Alnylam's (ALNY) RNAi candidate, patisiran, has been granted accelerated assessment by the European Medicines Agency. The company expects to file new drug application by end of 2017.
Glaxo's Subcutaneous Formulation of Benlysta Approved in EU
by Zacks Equity Research
GlaxoSmithKline's (GSK) Benlysta receives approval for a new subcutaneous formulation in Europe as an add-on therapy for patients with SLE.
The Zacks Analyst Blog Highlights: Micron Technology, Meritor, RH, Ultra Clean Holdings and Corcept Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Micron Technology, Meritor, RH, Ultra Clean Holdings and Corcept Therapeutics
5 Stocks That Doubled in 2017 and Can Keep Soaring Higher
by Nilanjan Choudhury
The strong stock rally does not necessarily indicate that all scrips would be wise picks.
Corcept (CORT) Q3 Earnings Miss Estimates, Guidance Raised
by Zacks Equity Research
Corcept Therapeutics' (CORT) earnings miss but sales beat expectations in the third quarter of 2017. The company remains focused on advancing its cortisol modulation platform.
Pfizer's sNDA for Bosulif Accepted in the U.S. and Europe
by Zacks Equity Research
Pfizer (PFE) along with Avillion announced that the regulatory authorities in the U.S. and Europe have accepted the application for label expansion of Bosulif to include newly diagnosed patients.
Top Ranked Momentum Stocks to Buy for August 29th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 29th:
Mylan and Otsuka Ink Agreement to Commercialize Deltyba
by Zacks Equity Research
Mylan (MYL) and Otsuka Pharmaceutical have entered into a license agreement to commercialize Deltyba in developing countries.
Adamas (ADMS) Dyskinesia Drug Gets FDA Approval, Stock Soars
by Zacks Equity Research
Adamas Pharmaceuticals' (ADMS) Gocovri was approved by the FDA for treating dyskinesia in patients with Parkinson's disease. This led to an upside in shares.
BioDelivery (BDSI) CEO Mark Sirgo to Retire by 2017 End
by Zacks Equity Research
BioDelivery Sciences (BDSI) President and CEO, Mark Sirgo, is set to retire this year.
Lannett (LCI) Q4 Earnings In Line, Stock Up on Solid View
by Zacks Equity Research
Lannett (LCI) reported in-line Q4 earnings and sales. The FDA approved multiple pending ANDAs during the quarter. Also, the company provided strong outlook for 2018.
Why Corcept Therapeutics (CORT) Could Be Positioned for a Surge
by Zacks Equity Research
Corcept Therapeutics (CORT) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Can The Uptrend Continue for Corcept Therapeutics (CORT)?
by Zacks Equity Research
Investors certainly have to be happy with Corcept Therapeutics Incorporated (CORT) and its short term performance
Top Ranked Momentum Stocks to Buy for August 7th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 7th:
Corcept (CORT) Looks Good: Stock Moves Up 8.8% in Session
by Zacks Equity Research
Corcept Therapeutics Incorporated (CORT) moved big last session, as its shares rose over 8% on the day.
Corcept (CORT) Q2 Earnings Beat Estimates, Guidance Raised
by Zacks Equity Research
Corcept Therapeutics Incorporated's (CORT) top line was driven by the strong sales of its only market drug Korlym. Thus the company raised its 2017 revenue guidance.
Vertex (VRTX) Triple Combination CF Studies Data Positive
by Zacks Equity Research
Vertex announced positive data from three studies evaluating three different triple combination regimens. These demonstrated pronounced improvements in lung function in CF patients.
Corcept Therapeutics Focuses on Korlym's Label Expansion
by Zacks Equity Research
We issued an updated research report on Corcept Therapeutics Incorporated (CORT) on Jul 12.
Why is Corcept's Stock Up More Than 60% So Far This Year?
by Zacks Equity Research
Shares of Corcept Therapeutics Incorporated (CORT) has soared 62.5% this year so far, massively outperforming the 5.6% increase registered by the Zacks classified Medical Drugs industry during this period.
Bristol-Myers (BMY) Beats on Q1 Earnings, Ups 2017 View
by Zacks Equity Research
Bristol-Myers Squibb Company's (BMY) first-quarter 2017 earnings of 84 cents per share beat the Zacks Consensus Estimate of 72 cents and surged 14% from the year-ago period.
Nivalis' (NVLS) Shares Down After Merger Deal with Alpine
by Zacks Equity Research
The announcement of Nivalis Therapeutics, Inc.'s (NVLS) merger agreement with a privately-held biotechnology company, Alpine Immune Sciences, Inc. failed to excite investors.
AMAG Files for FDA Approval of Subcutaneous Form of Makena
by Zacks Equity Research
AMAG Pharmaceuticals, Inc. (AMAG) announced the submission of a supplemental New Drug Application (sNDA) to the FDA for the subcutaneous auto-injector form of its marketed drug Makena in the U.S.
Corcept (CORT) Up 18% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Corcept (CORT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Corcept (CORT) Strives to Commercialize Key Drug Korlym
by Zacks Equity Research
We issued an updated report on Corcept Therapeutics Incorporated (CORT) on Mar 28.